Patrick Forsythe
vice-presidentMale0.0Global Dominance: 0.00%
Patrick Forsythe is the vice-president and general manager in Canada for Eisai, the pharmaceutical company that co-developed the Alzheimer's drug lecanemab, which has recently been approved by Health Canada. He expressed optimism about the drug's long-awaited approval, marking a significant advancement in Alzheimer's treatment.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Patrick Forsythe, vice-president and general manager of Eisai in Canada, stated that they are deeply troubled by the CDA’s draft recommendation.
Public drug plans shouldn’t cover new Alzheimer’s drug, Canada’s Drug Agency recommendsThe Globe and Mail·
Canada· 2026-02-19
Canada· 2026-02-19Also mentioned
Sara Mitchell
Patrick Forsythe is the vice-president and general manager in Canada for Eisai, which co-developed the drug with Biogen Inc.
Health Canada approves drug that slows progression of Alzheimer’s diseaseThe Globe and Mail·Canada· 2025-10-27
Canada· 2025-10-27
